KB001 ( DrugBank: KB001 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症2

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01695343
(ClinicalTrials.gov)
December 201225/9/2012Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic TreatmentA Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas AeruginosaCystic FibrosisBiological: KB001-A;Drug: Placebo ComparatorKaloBios PharmaceuticalsNULLCompleted12 Years50 YearsBoth182Phase 2United States;Australia;Israel;New Zealand
2NCT00638365
(ClinicalTrials.gov)
March 200812/3/2008Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas AeruginosaA Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas AeruginosaCystic FibrosisBiological: KB001;Other: PlaceboKaloBios PharmaceuticalsNULLCompleted12 YearsN/AAll27Phase 1/Phase 2United States